– ReCode Therapeutics announced the closing of an $80m Series B financing round co-led by Pfizer Ventures and EcoR1 Capital.
– The round was led by Pfizer Ventures and EcoR1 Capital.
– New investors include Sanofi Ventures, funds managed by Tekla Capital Management, Superstring Capital and NS Investment.
– Existing investors who participated included OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures, and Osage University Partners.

– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other well-validated but hard-to-drug targets, announced the closing of a $50m Series B financing.
– The financing was led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures.
– Proceeds from this financing will enable Jnana to progress its lead program for the treatment of phenylketonuria (PKU) into clinical development, while advancing a pipeline of additional programs and continuing to invest in its innovative and validated RAPID platform for the discovery of small molecule therapeutics for hard-to-drug targets.

– TRexBio, a discovery stage company decoding human tissue immune biology to create revolutionary therapeutics, announced the successful close of the final tranche of a $59m Series A financing.
– Proceeds from the financing will be used to expand the company’s unique discovery platform that maps human tissue regulatory T cell (Treg) behavior to dysregulation in disease, and to advance its six preclinical therapeutic programs.
– Investors include Eli Lilly and Company, SV Health, Johnson & Johnson Innovation, Pfizer Ventures, and Alexandria Venture Investments.
– TRexBio also announced the appointment of Johnston Erwin as Chief Executive Officer, and Ovid Trifan, M.D., Ph.D., as Chief Medical Officer, as part of the company’s plan to accelerate growth.

– Interius BioTherapeutics, a Philadelphia, PA-based preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene delivery, raised $76m in Series A financing.
– The round was co-led by Cormorant Asset Management and Fairmount Funds, and joined by Bain Capital Life Sciences, Pfizer Ventures, RA Capital Management, Longwood Fund, Logos Capital, Osage University Partners and Quan Capital.

– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.

– Mediar Therapeutics announced the completion of a seed extension funding round and welcomed Pfizer Ventures and Ono Venture Investment (OVI) as new syndicate members.
– The company is uniquely focused on the myofibroblast, a cell that is a key driver in fibrosis pathology.
– Mass General Brigham Ventures led an initial seed round in 2019 alongside other early venture investors.
– With Pfizer and OVI’s participation in the syndicate, the company has now raised $20m in total.
– The funding will support development of the firm’s unique myofibroblast discovery platform and will advance the company’s development of antibody treatments against a suite of novel targets.